April 2, 2021

The triplet regimen of nivolumab, ipilimumab, and panitumumab has shown antitumor activity and a consistent safety profile in patients with previously treated metastatic colorectal cancer that is microsatellite stable and KRAS, NRAS, and BRAF wild type, according to findings from the phase 2 LCCC1632 study.

Although chemotherapy is the mainstay of systemic treatment for advanced cholangiocarcinoma, there are limited treatment options when the disease progresses

The FDA has been leading an industry-wide evaluation of accelerated approvals of oncology drugs for which the clinical benefit was not verified in confirmatory trials.

Findings from a A phase 3 trial evaluating adjuvant nivolumab following surgery versus placebo demonstrated an improvement in median disease-free survival in patients with muscle-invasive urothelial cancer, according to results from the CheckMate 274 trial presented at the 2021 Genitourinary Cancers Symposium.

As a class, immune checkpoint inhibitor-based regimens outshine select targeted therapies in overall survival in patients with metastatic non–clear cell renal cell carcinoma.

It is not uncommon to have studies of nearly identical agents in nearly identical settings yield conflicting results, says Arjun V. Balar, MD.

Although curing advanced RCC is an admirable goal, there are many treatment options available on the horizon that result in substantial improvements in long-term outcomes.